TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.100nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.380nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.570nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.650nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.660nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.770nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 0.790nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 1.20nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 1.20nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 1.30nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 1.70nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 1.80nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 2.20nM ΔG°: -49.4kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 2.30nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 2.90nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 3.10nM ΔG°: -48.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 3.20nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 4nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 4nMAssay Description:Binding affinity to thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 4nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 5.30nM ΔG°: -47.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 9nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 10nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 11nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 13nM ΔG°: -45.0kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 14nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
Affinity DataKi: 19nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 19nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 20nM ΔG°: -43.9kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 20nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
Affinity DataKi: 22nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 22nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
Affinity DataKi: 26nM ΔG°: -43.3kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 27nM ΔG°: -43.2kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 29nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 30nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
Affinity DataKi: 32nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 33nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
Affinity DataKi: 34nM ΔG°: -42.6kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
Affinity DataKi: 36nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
Affinity DataKi: 36nM ΔG°: -42.5kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 40nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 42nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
Affinity DataKi: 44nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
TargetProthrombin(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research & Development
Curated by ChEMBL
Affinity DataKi: 47nMAssay Description:Binding affinity to human thrombinMore data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 50nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair
Affinity DataKi: 57nMAssay Description:Antagonist activity at full length human recombinant GCGR transfected in HEK293 cells assessed as inhibition of glucagon-stimulated cAMP by by LANCE ...More data for this Ligand-Target Pair
Affinity DataKi: 63nM ΔG°: -41.1kJ/molepH: 7.4 T: 2°CAssay Description:The progress of DPPIV inhibition by compounds was measured by recording the liberation of free pNA at 405 nm. IC50 was determined from the slope of r...More data for this Ligand-Target Pair
TargetComplement C1s subcomponent(Homo sapiens (Human))
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Johnson & Johnson Pharmaceutical Research And Development
Curated by ChEMBL
Affinity DataKi: 64nMAssay Description:Inhibition of Complement C1s subcomponentMore data for this Ligand-Target Pair